REFERENCES
1. Huh Y, Cho YJ, Nam GE. Recent epidemiology and risk factors of nonalcoholic fatty liver disease. J Obes Metab Syndr. 2022;31:17-27.
2. Wu T, Ye J, Mo S, et al. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians. J Gastroenterol Hepatol. 2024;39:1636-47.
3. Hershman M, Mei R, Kushner T. Implications of nonalcoholic fatty liver disease on pregnancy and maternal and child outcomes. Gastroenterol Hepatol (N Y). 2019;15:221-8.
4. Zhang ZC, Liu Y, Xiao LL, et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice. J Hepatol. 2015;63:1466-75.
5. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589-600.
6. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
7. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-50.
8. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
9. Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int. 2024;44:1051-60.
10. Hagström H, Höijer J, Ludvigsson JF, et al. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int. 2016;36:268-74.
11. Hong S, Lee SM, Kwak SH, et al. A comparison of predictive performances between old versus new criteria in a risk-based screening strategy for gestational diabetes mellitus. Diabetes Metab J. 2020;44:726-36.
12. Sarkar M, Grab J, Dodge JL, et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J Hepatol. 2020;73:516-22.
13. Herath RP, Siriwardana SR, Ekanayake CD, Abeysekara V, Kodithuwakku SUA, Herath HP. Non-alcoholic fatty liver disease and pregnancy complications among Sri Lankan women: a cross sectional analytical study. PLoS One. 2019;14:e0215326.
14. Qian Y, Zhang Y, Fan X, et al. Nonalcoholic fatty liver disease and adverse pregnancy outcomes in women with normal prepregnant weight. J Clin Endocrinol Metab. 2023;108:463-71.
15. Chai TY, Byth K, George J, Pasupathy D, Cheung NW. Elevated hepatic steatosis index is associated with the development of adverse maternal, but not adverse neonatal, outcomes: a retrospective cohort study. Int J Womens Health. 2023;15:589-98.
16. Zhou BG, Xia JL, Jiang X, Ding YB, She Q. Non-alcoholic fatty liver disease and gestational diabetes mellitus: a bidirectional two-sample mendelian randomization study. BMC Endocr Disord. 2024;24:40.
17. Niu C, Zhang J, Khalid N, et al. Cardiovascular complications during delivery hospitalizations in patients with nonalcoholic fatty liver disease in pregnancy. Eur J Gastroenterol Hepatol. 2024;36:1141-8.
18. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313-27.
19. Lechner K, McKenzie AL, Kränkel N, et al. High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation. Metab Syndr Relat Disord. 2020;18:176-85.
20. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713-23.
21. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94.
22. Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13:509-20.
23. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. BMJ. 2017;356:j1.
24. criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. Diabetes Res Clin Pract. 2014;103:341-63.
25. Woollett LA, Catov JM, Jones HN. Roles of maternal HDL during pregnancy. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867:159106.
26. Liu PJ, Liu Y, Ma L, et al. The predictive ability of two triglyceride-associated indices for gestational diabetes mellitus and large for gestational age infant among chinese pregnancies: a preliminary cohort study. Diabetes Metab Syndr Obes. 2020;13:2025-35.
27. Brereton MF, Rohm M, Shimomura K, et al. Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic β-cells. Nat Commun. 2016;7:13496.
29. National Health and Family Planning Commission of the People’s Republic of China. Criteria of weight for adults (WS/T 428-2013). Beijing: Standards Press of China; 2013. (In Chinese) Available from: https://www.nhc.gov.cn/wjw/yingyang/201308/a233d450fdbc47c5ad4f08b7e394d1e8.shtml. [Last accessed on 28 Jul 2025].
30. National Health Commission of the People’s Republic of China. Standard of recommendation for weight gain during pregnancy period (WS/T 801-2022). Beijing: Standards Press of China; 2022. (In Chinese) Available from: https://www.nhc.gov.cn/wjw/c100311/202208/deb61e5c2299451ea1b957b0672272b3.shtml.
31. Graif M, Yanuka M, Baraz M, et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol. 2000;35:319-24.
32. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-74.
33. Metzger BE, Gabbe SG, Persson B, et al; International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676-82.
34. American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Hypertension in pregnancy: report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122-31.
35. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75-84.
36. National Health Commission of the People’s Republic of China. Growth standard for newborns by gestational age (WS/T 800-2022). Beijing: Standards Press of China; 2022. (In Chinese) Available from: https://www.nhc.gov.cn/wjw/c100311/202208/07787ef64ba34fe1bc8bbdae9fd0d4e5.shtml. [Last accessed on 28 Jul 2025].
37. Borovac-Pinheiro A, Pacagnella RC, Cecatti JG, et al. Postpartum hemorrhage: new insights for definition and diagnosis. Am J Obstet Gynecol. 2018;219:162-8.
38. Committee on Practice Bulletins-Obstetrics. Practice bulletin No. 183: postpartum hemorrhage. Obstet Gynecol. 2017;130:e168-86.
39. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ. 2002;325:157-60.
40. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371:1131-41.
41. Choudhury AA, Devi Rajeswari V. Gestational diabetes mellitus - a metabolic and reproductive disorder. Biomed Pharmacother. 2021;143:112183.
42. Nasioudis D, Doulaveris G, Kanninen TT. Dyslipidemia in pregnancy and maternal-fetal outcome. Minerva Ginecol. 2019;71:155-62.
43. Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010;2010:1-10.
44. Richard AJ, White U, Elks CM, Stephens JM. Adipose tissue: physiology to metabolic dysfunction. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555602/. [Last accessed on 21 Jul 2025].
45. Coates D, Homer C, Wilson A, et al. Indications for, and timing of, planned caesarean section: a systematic analysis of clinical guidelines. Women Birth. 2020;33:22-34.
46. Lee SM, Jung YM, Choi ES, et al. Metabolic dysfunction-associated fatty liver disease and subsequent development of adverse pregnancy outcomes. Clin Gastroenterol Hepatol. 2022;20:2542-50.e8.
48. Svenvik M, Raffetseder J, Brudin L, et al. Early prediction of spontaneous preterm birth before 34 gestational weeks based on a combination of inflammation-associated plasma proteins. Front Immunol. 2024;15:1415016.
49. Ismaiel A, Dumitraşcu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review. Front Med. 2019;6:202.
50. Scifres CM, Davis EM, Orris S, et al. Metabolic factors and perinatal outcomes among pregnant individuals with mild glucose intolerance. Diabetes Res Clin Pract. 2024;216:111830.
51. Byrne CD. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc. 2013;72:412-9.
52. Lastra G, Dhuper S, Johnson MS, Sowers JR. Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol. 2010;7:577-84.
53. Metzger BE, Lowe LP, Dyer AR, et al; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991-2002.
